Drugs / AMDIZALISIB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03786926 | Aug 2019 → Jun 2024 | lymphoma | Hutchmed | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03128164 | Aug 2017 → Aug 2023 | lymphoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT02631642 | Mar → Oct 2016 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05713110 | Feb 2023 → Dec 2024 | lymphoma | Hutchmed | Completed | No outcome recorded |
| Phase 2 | NCT04849351 | Apr 2021 → Feb 2024 | follicular lymphoma, marginal zone lymphoma | Hutchison Medipharma Limited | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-06-09 | Hutchison Medipharma Limited | Results HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings hutch-med.com ↗
Median duration of response (“DoR”) and progression free survival (“PFS”) were not reached for the 26 efficacy evaluable patients in the FL cohort. |
| 2021-09-13 | Hutchison Medipharma Limited | Regulatory HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma hutch-med.com ↗
The granting of BTD to amdizalisib by the NMPA underscores the promising clinical value of this highly selective and potent PI3Kδ inhibitor. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMDIZALISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4438249 ↗ |
| Known as | HMPL-689 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04849351 ↗ |
| Action | Inhibit | “selective PI3Kδ inhibitor” NCT02631642 ↗ |
| Modality | Small molecule | “selective and potent small molecule inhibitor” NCT03786926 ↗ |
| Route | Oral | “single oral doses of HMPL-689” NCT02631642 ↗ |